Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

Ferrara, 2003, The biology of VEGF and its receptors, Nat Med, 9, 669, 10.1038/nm0603-669 Dvorak, 2002, Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy, J Clin Oncol, 20, 4368, 10.1200/JCO.2002.10.088 Miller, 2007, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N Engl J Med, 357, 2666, 10.1056/NEJMoa072113 Miles, 2010, Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer, J Clin Oncol, 28, 3239, 10.1200/JCO.2008.21.6457 Gray, 2009, Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer, J Clin Oncol, 27, 4966, 10.1200/JCO.2008.21.6630 Robert, 2011, RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of Human Epidermal Growth Factor Receptor 2-negative, locally recurrent or metastatic breast cancer, J Clin Oncol, 29, 1252, 10.1200/JCO.2010.28.0982 Brufsky, 2010, Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC), J Clin Oncol, 28, 10.1200/jco.2010.28.15_suppl.1021 Miller, 2005, Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer, J Clin Oncol, 23, 792, 10.1200/JCO.2005.05.098 Cobleigh, 2003, A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer, Semin Oncol, 30, 117, 10.1053/j.seminoncol.2003.08.013 2008, Genentech, Inc. Avastin® (Bevacizumab) FDA Drug Label Hapani, 2009, Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis, Lancet Oncol, 10, 559, 10.1016/S1470-2045(09)70112-3 Nalluri, 2008, Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis, JAMA, 300, 2277, 10.1001/jama.2008.656 Scappaticci, 2007, Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab, J Natl Cancer Inst, 99, 1232, 10.1093/jnci/djm086 National Cancer InstituteCommon Terminology Criteria for Adverse Events.http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (15 December 2010, date last accessed). Moher, 1999, Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses, Lancet, 354, 1896, 10.1016/S0140-6736(99)04149-5 Sweeting, 2004, What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data, Stat Med, 23, 1351, 10.1002/sim.1761 DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2 Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 Begg, 1994, Operating characteristics of a rank correlation test for publication bias, Biometrics, 50, 1088, 10.2307/2533446 Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 Geiger-Gritsch, 2010, Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials, Oncologist, 15, 1179, 10.1634/theoncologist.2009-0155 Choueiri, 2011, Congestive heart failure risk in patients with breast cancer treated with bevacizumab, J Clin Oncol, 29, 632, 10.1200/JCO.2010.31.9129 Cortes, 2009, Risk of venous thromboembolism with bevacizumab in cancer patients, JAMA, 301, 1434, 10.1001/jama.2009.440 Verma, 2011, Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side?, J Clin Oncol, 29, 603, 10.1200/JCO.2010.32.9060 Sugrue, 2006, Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy, J Clin Oncol, 24, 10.1200/jco.2006.24.18_suppl.3535 Saif, 2007, Gastrointestinal perforation due to bevacizumab in colorectal cancer, Ann Surg Oncol, 14, 1860, 10.1245/s10434-006-9337-9 Smith, 2010, First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients, Ann Oncol, 22, 595, 10.1093/annonc/mdq430